MALAT1 and Hyperglycemia: The novelty of our study is that the combined use of two lncRNAs, LIPCAR and MALAT1, measured in the plasma of ACS patients, may discriminate vulnerable CAD from SA, correlate with hyperglycemia in UA patients, and predict unfavorable evolution (MACE) of STEMI patients.